Edgewise Therapeutics opened lower at $46.46, compared with its previous close of $47.57. In the last trading session, the stock traded between $45.04 and $46.93. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Edgewise Therapeutics is now worth
$ 229.48
Giving a profit of
$ 129.48 (129.48%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 12 Analysts
Buy
83.33%
Hold
16.67%
Sell
0%
Markets Today
Today's Change
$-1.79 (-3.76%)
Day High
$46.93
Day Low
$45.04
Day Open
$46.46
Prev Close
$47.57
Volume
8,68,406
1W Return
21.95%
1M Return
19.05%
3M Return
3.32%
6M Return
32.47%
1Y Return
113.14%
Fundamentals
Market Cap ($ Mn)
5,012
PE Ratio
-
PB Ratio
10.29
PEG Ratio
-
ROE
-32.79%
ROCE
-37.16%
EPS (TTM)
$10.65
Investment Returns
1 Week
21.95%
1 Month
19.05%
3 Months
3.32%
6 Months
32.47%
9 Months
49.32%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
16Oct
William Blair initiates coverage on Edgewise Therapeutics with Outperform
William Blair initiated coverage on Edgewise Therapeutics. Analyst Alethia Young assigned an Outperform rating. No price target or financial estimates were disclosed.
27 days ago
20Jul
Evercore ISI raises Edgewise Therapeutics target to $55
Evercore ISI Group analyst Cory Kasimov maintained an Outperform rating on Edgewise Therapeutics and raised the price target from $45 to $55.
3mo ago
6Jul
Guggenheim raises Edgewise Therapeutics target to $51
Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating on Edgewise Therapeutics and raised the price target from $41 to $51.
4mo ago
17Jun
RBC Capital raises Edgewise Therapeutics price target to $59
RBC Capital analyst Leonid Timashev maintained an Outperform rating on Edgewise Therapeutics and raised the price target to $59 from $48, signaling a positive outlook.
4mo ago
17Jun
Goldman Sachs raises Edgewise Therapeutics target to $32
Goldman Sachs analyst Paul Choi maintains a Neutral rating on Edgewise Therapeutics and raises the price target to $32 from $20, signaling a revised valuation perspective.
4mo ago
16Jun
Edgewise Therapeutics reports improvements in HCM trial
Edgewise Therapeutics Inc. announced topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial, showing EDG-7500 improved heart function, symptoms, and biomarkers in both obstructive and nonobstructive HCM patients. The study of 53 patients revealed significant reductions in LVOT-G and NT-proBNP levels, with improvements in NYHA functional class. The drug was generally well tolerated with no LVEF reductions below 50%.
